Gensight Biologics S.a annual total assets
2020
2021
2022
2023
2024
2025
Gensight Biologics S.a Total Assets Growth & History (SIGHT)
Gensight Biologics S.a's total assets was €8.3M for fiscal 2025.
View full Gensight Biologics S.a company overviewGensight Biologics S.a annual total assets history
| Fiscal year | Period ended | Total assets | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €8.3M | −€2.5M | −23.24% |
| 2024 | 2024-12-31 | €10.8M | €1.6M | +17.78% |
| 2023 | 2023-12-31 | €9.1M | −€16.8M | −64.80% |
| 2022 | 2022-12-31 | €25.9M | −€30.7M | −54.21% |
| 2021 | 2021-12-31 | €56.6M | €9.3M | +19.61% |
| 2020 | 2020-12-31 | €47.4M | — | — |
Gensight Biologics S.a quarterly total assets
Q4.24
Q4.25
| Fiscal quarter | Period ended | Total assets | Change | YoY change |
|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | €8.3M | −€2.5M | −23.24% |
| Q4 2024 | 2024-12-31 | €10.8M | — | — |
Gensight Biologics S.a total assets trends
Over the last five fiscal years, Gensight Biologics S.a's total assets decreased from €47.4M to €8.3M, a change of −€39.1M. The latest reported quarter, Q4 2025, shows €8.3M.
About the metric
What total assets mean
Total assets are the resources a company controls at a reporting-period end, including cash, investments, receivables, inventory, property, intangible assets, and other reported assets. The composition of assets differs substantially by industry.
Calculation and source
reported total assets
TickerStat uses total assets reported in company official filings. When a filer provides the equivalent balance-sheet total as liabilities and equity, that reported amount is used because total assets must equal total liabilities plus equity. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Gensight Biologics S.a source filings ↗Community posts
GenSight advances LUMEVOQ manufacturing transfer to Catalent
GenSight ($SIGHT) said an engineering batch of GS010/LUMEVOQ at Catalent was produced as planned, with viral genome concentration meeting target specifications. Preparations have begun for a GMP-standard batch to supply special-access progr ...